Clinical pharmacology of cardio-oncology: a novel interdisciplinary platform for basic and translational research

DOI Web Site Web Site PubMed 21 References
  • Sase Kazuhiro
    Clinical Pharmacology and Regulatory Science, Graduate School of Medicine, Juntendo University

Bibliographic Information

Other Title
  • 重要性を増すcardio-oncology：新たな学際領域研究の現状と今後の方向性
  • ジュウヨウセイ オ マス cardio-oncology : アラタ ナ ガクサイ リョウイキ ケンキュウ ノ ゲンジョウ ト コンゴ ノ ホウコウセイ

Search this article

Abstract

<p>Advances in cancer treatment have led to dramatic increase in cancer survivors. In addition to cardiotoxicity resulting from anthracyclines and radiation therapy, the emergence of novel cancer treatment-related cardiovascular disease (CTRCD) with molecularly targeted therapies and immune checkpoint inhibitors has been recognized as an unmet medical need. Cardio-oncology is a new interdisciplinary research opportunity at the intersection of cardiovascular disease and cancer. Research priorities need to be identified for diagnosis, treatment, and prevention of previously unknown CTRCD(s), including (a) cardiac dysfunction and heart failure, (b) coronary artery disease, (c) valvular disease, (d) arrhythmias and QT-prolongation, (e) arterial hypertension, (f) thromboembolic disease, and (g) other cardiovascular disorders. In particular, understanding the fundamental mechanisms underlying CTRCD is essential for developing new methods. Applying more appropriate disease models and more effective methods for toxicity screening will help to better understand CTRCD. Although animal models have been used to predict potential problems, more advanced predictive models are also needed. Biobanks and other specimens with patient registries are expected to facilitate the validation of new biomarkers, genomic analysis, and imaging methods.</p>

Journal

References(21)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top